Sign in

Private company

CONCERT PHARMACEUTICALS, INC.

Pharmaceutical preparations company1

In its 2022 annual report the company says: “We are a late-stage clinical biopharmaceutical company that is developing CTP-543, a Janus Kinase 1 and Janus Kinase 2 (JAK 1/2) inhibitor that we discovered through the application of our DCE Platform ® (deuterated chemical entity platform). We are evaluating CTP-543 in a Phase 3 clinical program for the treatment of alopecia areata, a serious autoimmune dermatological condition.”49 It is headquartered in Lexington, Massachusetts.1

Last updated Oct 21, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersLexington, Massachusetts1
  • Business address65 Hayden Avenue, Suite 3000N, Lexington, Ma 024212
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2021

-237.9%Operating margin3
-245.7%Net margin3
312.3%Revenue growth, 20213
-71.3%Return on equity3
-$55.4MFree cash flow3

Where the money goes

Where each dollar of revenue went, fiscal 2021

  • Research and development100¢$87.6M

Out of $32.6M in revenue.3 The company lost money this year.

Financial statements

Revenue45673$32.6M in 2021−51% since 2015
0$50.0M$100.0M$150.0M2015: $66.7M$66.7M20152016: $174.0K$174.0K2016−100%2017: $143.9M$143.9M2017+82596%2018: $10.5M$10.5M2018−93%2019: $1.1M$1.1M2019−90%2020: $7.9M$7.9M2020+634%2021: $32.6M$32.6M2021+312%
Operating income45673-$77.5M in 2021
-$100.0M-$50.0M0$50.0M$100.0M2015: $24.8M$24.8M20152016: -$51.2M-$51.2M20162017: $92.6M$92.6M20172018: -$55.6M-$55.6M20182019: -$79.0M-$79.0M2019+42%2020: -$72.6M-$72.6M2020−8%2021: -$77.5M-$77.5M2021+7%
Net income45673-$80.1M in 2021
-$100.0M-$50.0M0$50.0M$100.0M2015: $24.2M$24.2M20152016: -$50.7M-$50.7M20162017: $95.6M$95.6M20172018: -$56.0M-$56.0M20182019: -$78.2M-$78.2M2019+40%2020: -$74.8M-$74.8M2020−4%2021: -$80.1M-$80.1M2021+7%
Fiscal year2015201620172018201920202021
Revenue$66.7M4$174.0K5$143.9M5$10.5M6$1.1M7$7.9M3$32.6M3
Research and development$28.9M4$37.0M5$30.2M5$43.1M6$59.8M7$61.6M3$87.6M3
Operating expenses$110.1M3
Operating income$24.8M4-$51.2M5$92.6M5-$55.6M6-$79.0M7-$72.6M3-$77.5M3
Income tax$429.0K4$05-$300.0K5$313.0K6$07-$85.0K3$03
Net income$24.2M4-$50.7M5$95.6M5-$56.0M6-$78.2M7-$74.8M3-$80.1M3
Earnings per share$1.144-$2.285$4.205-$2.405-$2.403-$2.333
Earnings per share (diluted)$1.094-$2.285$4.065-$2.405-$2.403-$2.333
Shares (weighted, basic)34.4M shares3
Shares (weighted, diluted)34.4M shares3

Compare CONCERT PHARMACEUTICALS, INC. with another company

Corporate structure

CONCERT PHARMACEUTICALS, INC. sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of CONCERT PHARMACEUTICALS, INC.

  • CONCERT PHARMACEUTICALS, INC. Lexington, Massachusetts

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What CONCERT PHARMACEUTICALS, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Leasehold improvements$5.0M3 Dec 31, 2021$5.0M3 Dec 31, 20200%
Property and equipment, before depreciation$9.4M3 Dec 31, 2021$10.4M3 Dec 31, 2020−9.8%
Accumulated depreciation$4.1M3 Dec 31, 2021$4.0M3 Dec 31, 2020+2.8%
Property and equipment, net$5.2M3 Dec 31, 2021$6.4M3 Dec 31, 2020−17.6%
Operating-lease assets (leased space)$8.6M3 Dec 31, 2021$9.0M3 Dec 31, 2020−4.3%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$141.6M3 Dec 31, 2021$77.2M3 Dec 31, 2020+83.5%
Marketable securities, current$1.5M3 Dec 31, 2021$2.0M3 Dec 31, 2020−25.7%

Leadership

Who has led CONCERT PHARMACEUTICALS, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Roger D. Tung2014–2023

Chief financial officer

  1. D. Ryan Daws2014–2017

Chief operating officer

  1. Nancy Stuart2014–2023
201520202025
Board members and other officers (18)

Former names

  • CONCERT PHARMACEUTICALS INCJun 16, 2006 to May 9, 20082

Timeline

  1. Mar 6, 20238-K Completed an acquisition or sale; Listing notice or transfer; Change to shareholders' rights31
  2. Jan 19, 20238-K Entered a material agreement; Other events32
  3. Nov 7, 20228-K Results of operations33
  4. Aug 22, 20228-K Other events34
  5. Aug 4, 20228-K Results of operations; Other events35
  6. Jun 13, 20228-K Shareholder vote; Other events36
  7. Jun 3, 20228-K Entered a material agreement; Other events37
  8. May 23, 20228-K Regulation FD disclosure; Other events38
  9. May 12, 20228-K Other events39
  10. May 5, 20228-K Results of operations40
  11. Mar 3, 20228-K Results of operations41
  12. Feb 3, 20228-K Executive or director change42
  13. Feb 12, 2014New chief executive Roger D. Tung becomes CEO11

Calendar

When it reported results

  1. Nov 7, 2022Reported quarterly or annual results33
  2. Aug 4, 2022Reported quarterly or annual results35
  3. May 5, 2022Reported quarterly or annual results40
  4. Mar 3, 2022Reported quarterly or annual results41
  5. Nov 9, 2021Reported quarterly or annual results43

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

112 filings to the SEC since October 2021: 1 annual reports, 4 quarterly reports, 14 major events, 50 insider forms, 9 large holders, 34 other. The latest 20:

  1. Mar 16, 202315-12G EDGAR
  2. Mar 13, 2023EFFECT EDGAR
  3. Mar 13, 2023EFFECT EDGAR
  4. Mar 13, 2023EFFECT EDGAR
  5. Mar 13, 2023EFFECT EDGAR
  6. Mar 6, 20234 FORM 4 SUBMISSION EDGAR
  7. Mar 6, 20234 FORM 4 SUBMISSION EDGAR
  8. Mar 6, 20234 FORM 4 SUBMISSION EDGAR
  9. Mar 6, 20234 FORM 4 SUBMISSION EDGAR
  10. Mar 6, 20234 FORM 4 SUBMISSION EDGAR
  11. Mar 6, 20234 FORM 4 SUBMISSION EDGAR
  12. Mar 6, 20234 FORM 4 SUBMISSION EDGAR
  13. Mar 6, 20234 FORM 4 SUBMISSION EDGAR
  14. Mar 6, 20234 FORM 4 SUBMISSION EDGAR
  15. Mar 6, 20234 FORM 4 SUBMISSION EDGAR
  16. Mar 6, 20234 FORM 4 SUBMISSION EDGAR
  17. Mar 6, 2023S-8 POS EDGAR
  18. Mar 6, 2023S-8 POS EDGAR
  19. Mar 6, 2023S-8 POS EDGAR
  20. Mar 6, 2023S-8 POS EDGAR

The 112 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

28 open-market trades by officers, directors and large owners since October 2021: 3 buys and 25 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Feb 15, 2023Stuart NancyChief Operating OfficerSale6,048$8.33$50.4KForm 4
Feb 15, 2023Munsie Jeffrey AChief Legal OfficerSale3,762$8.34$31.4KForm 4
Feb 15, 2023Cassella James VChief Development OfficerSale3,762$8.34$31.4KForm 4
Feb 15, 2023Becker Marc A.Chief Financial OfficerSale3,762$8.33$31.3KForm 4
Jan 30, 2023Stuart NancyChief Operating OfficerSale13,200$8.35$110.2KForm 4
Jan 30, 2023Munsie Jeffrey AChief Legal OfficerSale8,493$8.35$70.9KForm 4
Jan 30, 2023Cassella James VChief Development OfficerSale10,106$8.35$84.4KForm 4
Jan 30, 2023Becker Marc A.Chief Financial OfficerSale8,493$8.35$70.9KForm 4
Jan 6, 2023Tung Roger DChief Executive OfficerSale9,240$7.24$66.9KForm 4
Jan 6, 2023Stuart NancyChief Operating OfficerSale2,893$7.25$21.0KForm 4
Jan 6, 2023Munsie Jeffrey AChief Legal OfficerSale2,893$7.25$21.0KForm 4
Jan 6, 2023Cassella James VChief Development OfficerSale2,893$7.25$21.0KForm 4
Jan 6, 2023Becker Marc A.Chief Financial OfficerSale2,893$7.25$21.0KForm 4
Oct 14, 2022HUTT PETER BARTONDirectorSale3,539$6.09$21.6KForm 4
Jun 6, 2022van Heek ChristiDirectorBuy10,526$4.75$50.0KForm 4
Jun 6, 2022Auchincloss Thomas GDirectorBuy6,000$4.75$28.5KForm 4
Jun 6, 2022ALDRICH RICHARDDirectorBuy210,526$4.75$1.0MForm 4
Feb 15, 2022Tung Roger DChief Executive OfficerSale13,480$3.09$41.7KForm 4
Feb 14, 2022Stuart NancyChief Operating OfficerSale6,049$3.08$18.6KForm 4
Feb 14, 2022Munsie Jeffrey AChief Legal OfficerSale3,762$3.09$11.6KForm 4

All 28 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How CONCERT PHARMACEUTICALS, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARCONCERT PHARMACEUTICALS, INC.1
  • CIK0001367920
  • Filer statusNon-accelerated filer<br>smaller reporting company1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • Business address65 Hayden Avenue, Suite 3000N, Lexington, MA 024211
  • Phone781-860-00451
  • Shares outstanding47,938,188 as of Nov 1, 20229
  • Public float$100.7M as of Jun 30, 20213
  • On EDGAR sinceJun 16, 20061
  • Filings583 in all: 4 (256), 8-K (84), SC 13G/A (37), 3 (31), 10-Q (27), SC 13G (22), DEFA14A (13), 10-K (9)1
    All 42 form types

    EFFECT (9), S-8 (9), S-8 POS (9), 424B5 (8), DEF 14A (8), 4/A (7), CORRESP (7), UPLOAD (6), POS AM (4), S-3 (4), REGDEX (3), SC TO-C (3), CT ORDER (2), PRE 14A (2), SC 14D9/A (2), SC TO-T/A (2), SC14D9C (2), 15-12G (1), 25-NSE (1), 3/A (1), 424B4 (1), 5 (1), 5/A (1), 8-A12B (1), CERTNAS (1), DRS (1), DRS/A (1), FWP (1), S-1 (1), S-1/A (1), S-1MEF (1), SC 13D (1), SC 14D9 (1), SC TO-T (1)

  • Latest filingsAnnual report (10-K) Mar 3, 2022
    Quarterly report (10-Q) Nov 7, 2022
    Proxy statement (DEF 14A) Apr 26, 2022
    Latest 8-K (8-K) Mar 6, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
    SEC EDGAROther events
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
    SEC EDGAROther events
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49